FRA
IMMU

Front Row Advisors’s Immunomedics Inc IMMU Stock Holding History

Front Row Advisors’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,000
Closed -$35K – 1057
2020
Q2 		$35K Buy
+1,000
New +$29.2K 0.02% 262
2020
Q1 		– Sell
-500
Closed -$11K – 1075
2019
Q4 		$11K Hold
500
– – 0.01% 449
2019
Q3 		$7K Buy
+500
New +$7.35K 0.01% 541

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Front Row Advisors's IMMU Position: Q3 2020 in Review

Front Row Advisors sold out of Immunomedics Inc (IMMU) in Q3 2020, closing a stake of 1,000 shares — an estimated $35K sold.

Front Row Advisors first reported a position in IMMU in Q3 2019 and held it in 3 quarters. The position peaked at $35K in Q2 2020. 408 funds tracked by Wall St. Rank hold IMMU as of Q3 2020.

  • Front Row Advisors reported no remaining Immunomedics Inc position as of Q3 2020 after selling out during the quarter.
  • Front Row Advisors sold 1,000 Immunomedics Inc shares in Q3 2020, an estimated $35K.
  • Front Row Advisors first reported a position in Immunomedics Inc in Q3 2019 and held it in 3 quarters.
  • Front Row Advisors's Immunomedics Inc position peaked at $35K in Q2 2020.
  • 408 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2020.

Based on Front Row Advisors's 13F filing for Q3 2020, filed 30 Nov 2020.